Here we investigate the potential influence of TEVs on the efficacy of CD171-specific CAR T cells from CD4+ and CD8+ T cell subsets in preclinical neuroblastoma models and assess a potential differential involvement of neurotrophin receptors in this process. This evidence concerns the gene CD4 and neuroblastoma.